Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM3500
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
VM3500 is a long-acting injectable small molecule drug in preclinical development for the treatment of HIV-1 infection. It acts as a novel integrase strand transfer inhibitor (INSTI), targeting the HIV integrase enzyme to prevent viral DNA integration into the host genome. The drug is being developed by Viriom as part of combination antiretroviral therapy regimens for HIV-1 infection[1][4][5].
- Other names
- VM 3500VM3500VM-3500
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on VM3500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM3500.